gastropell forte oral paste for horses
randlab australia pty ltd - omeprazole - oral paste - omeprazole imidazole active 100.0 mg/ml - alimentary system
equibactin vet. (333 mg/g + 67 mg/g) oral paste for horses
le vet bv - trimethoprim; sulfadiazine - oral paste - 66.7, 333.3 milligram(s)/gram - sulfadiazine and trimethoprim - horses - antibacterial
eqvalan oral paste for horses 18.7 mg/g
boehringer ingelheim vetmedica gmbh - ivermectin - oral paste - 18.7 milligram(s)/gram - ivermectin
noropraz, 18.7 mg/g + 140.3 mg/g oral paste for horses
norbrook laboratories (ireland) limited - ivermectin; praziquantel - oral paste - 18.7, 140.3 milligram(s)/gram - ivermectin, combinations
iverpraz, 18.7 mg/g + 140.3 mg/g oral paste for horses
norbrook laboratories (ireland) limited - ivermectin; praziquantel - oral paste - 18.7, 140.3 milligram(s)/gram - ivermectin, combinations
nexmectin 18.7 mg/g oral paste for horses
eco animal health europe limited - ivermectin - oral paste - 18.7 milligram(s)/gram - ivermectin
promec 18.7 mg/g oral paste for horses
eco animal health europe limited - ivermectin - oral paste - 18.7 milligram(s)/gram - ivermectin
dukoral oral inactivated cholera vaccine liquid vial and buffer powder sachet
seqirus pty ltd - vibrio cholerae, quantity: 31.25 billion organisms; vibrio cholerae, quantity: 1 mg - oral liquid, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate dihydrate; water for injections; monobasic sodium phosphate dihydrate - cholera caused by serogroup 01 vibrio cholerae: active immunisation of adults and children from two years of age, who will be visiting areas epidemic or endemic for cholera and who are at high risk of infection.
equipalazone oral paste
dechra veterinary products (australia) pty. ltd. - phenylbutazone - oral paste - phenylbutazone analgesic active 200.0 mg/ml - musculoskeletal system
olanzapine tablet, orally disintegrating
macleods pharmaceuticals limited - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was es